News attention
20
2020
-
03
Next Generation Genetics and Gene Editing
Scientists have also made significant progress in the field of gene editing. Among the most remarkable achievements this year, the United States launched the first clinical trial involving CRISPR treated cells, and began to conduct high-quality editing. The newly established Genomics Research laboratory may be carrying out more gene editing innovation, which is a facility established by cooperation between GSK plc and the original pioneer of CRISPR.

Gene sequencing technology is becoming cheaper, more accurate, and available to researchers, expanding the range of applications from diagnostics to drug development. In fact, many of these technologies are available to everyday consumers to provide information about the genetic risk of disease and guide treatment decisions. This, in turn, will help consumers make more informed medical decisions as they become familiar with the onset and progression of the disease. Companies such as 23andMe, Myriad Genetics and Invitae Corp. are expected to dominate the direct-to-consumer market and are expected to benefit from a market expected to be worth more than $2023 million by 9.
Scientists have also made great strides in the field of gene editing. Among the most notable achievements of the year, the United States launched the first clinical trial involving CRISPR-treated cells and began performing quality editing. More gene-editing innovations may be underway at the newly formed Genomics Research lab, a facility established in collaboration between GlaxoSmithKline and CRISPR's original pioneers. | ![]() |
![]() |
As the cost of these advanced genetic tools falls, PwC predicts that genetic testing will become part of mainstream medical practice in some countries, while pharmaceutical companies could spend 20 percent of their R&D budgets on genetics and genomics in the new decade. |
RELATED NEWS